We’re pleased to announce that in collaboration with Daiichi-Sankyo and AstraZeneca, Lumanity has been named a BOBI Award finalist in the Best Patient-Centric Approach category.
The award recognizes a market research or analytical project that demonstrates a positive impact by putting patients at the heart of decision making.
Our submission focused on the global launch of a brand across multiple triple-negative breast cancer (TNBC) indications, for which Lumanity conducted a comprehensive, multi-country patient journey study. The challenge was not simply to map clinical steps, but to reveal the raw, emotional truths and unmet needs shaping every moment of the journey. These insights now anchor the global launch strategy, reframing messaging around empathy, empowerment, and shared understanding, keeping the patient and their experience at the center.
Congratulations to Lumanity’s Rob Rawlinson, Andrew Wood, Tanya Mubayiwa, and Harpreet Kaur, and the teams from Daiichi-Sankyo and AstraZeneca for this recognition, and to all the other finalists! Winners will be announced at the BOBI Awards Ceremony on April 27, 2026.
